Cristália Produtos Químicos Farmacêuticos Ltda.   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Sao Paulo Brazil (1972)
Status: No NME R&D (1972)

Organization Overview

First Clinical Trial
2007
NCT00523289
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cristália Produtos Químicos Farmacêuticos Ltda.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Coronary Artery Disease (Phase 4)

Coronavirus Infections (Phase 3)

Erectile Dysfunction (Phase 4)

Hand Injuries (Phase 4)

Hyperhidrosis (Phase 3)

Infections (Phase 3)

Intracranial Hemorrhages (Phase 4)

Leprosy (Phase 3)

Leukemia (Phase 3)

Musculoskeletal Diseases (Phase 3)

Neuralgia (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Viral (Phase 3)

Pressure Ulcer (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Spinal Diseases (Phase 3)

Stroke (Phase 4)

Thromboembolism (Phase 3)

Ulcer (Phase 3)

Venous Thromboembolism (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial APIs: 21